Email updates

Keep up to date with the latest news and content from BMC Pharmacology and Toxicology and BioMed Central.

Open Access Highly Accessed Research article

Hit identification of IKKβ natural product inhibitor

Chung-Hang Leung1*, Daniel Shiu-Hin Chan2, Ying-Wei Li3, Wang-Fun Fong3 and Dik-Lung Ma2*

Author Affiliations

1 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China

2 Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong

3 Centre for Cancer and Inflammation Research, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Hong Kong

For all author emails, please log on.

BMC Pharmacology and Toxicology 2013, 14:3  doi:10.1186/2050-6511-14-3


The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/2050-6511/14/3


Received:15 November 2011
Accepted:21 December 2012
Published:7 January 2013

© 2013 Leung et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The nuclear factor-κB (NF-κB) proteins are a small group of heterodimeric transcription factors that play an important role in regulating the inflammatory, immune, and apoptotic responses. NF-κB activity is suppressed by association with the inhibitor IκB. Aberrant NF-κB signaling activity has been associated with the development of cancer, chronic inflammatory diseases and auto-immune diseases. The IKK protein complex is comprised of IKKα, IKKβ and NEMO subunits, with IKKβ thought to play the dominant role in modulating NF-κB activity. Therefore, the discovery of new IKKβ inhibitors may offer new therapeutic options for the treatment of cancer and inflammatory diseases.

Results

A structure-based molecular docking approach has been employed to discover novel IKKβ inhibitors from a natural product library of over 90,000 compounds. Preliminary screening of the 12 highest-scoring compounds using a luciferase reporter assay identified 4 promising candidates for further biological study. Among these, the benzoic acid derivative (1) showed the most promising activity at inhibiting IKKβ phosphorylation and TNF-α-induced NF-κB signaling in vitro.

Conclusions

In this study, we have successfully identified a benzoic acid derivative (1) as a novel IKKβ inhibitor via high-throughput molecular docking. Compound 1 was able to inhibit IKKβ phosphorylation activity in vitro, and block IκBα protein degradation and subsequent NF-κB activation in human cells. Further in silico optimization of the compound is currently being conducted in order to generate more potent analogues for biological tests.

Background

The nuclear factor-κB (NF-κB) proteins are a small group of heterodimeric transcription factors that play an important role in regulating inflammatory, immune, and apoptotic responses [1-3]. NF-κB is ubiquitously present in the cytoplasm and its activity is normally suppressed by association with inhibitor IκB [4]. The intracellular NF-κB signaling cascade is initiated by a variety of inducers including proinflammatory cytokines TNF-α, IL-1 or endotoxins [5,6]. The aberrant activity to the NF-κB signaling pathway has been implicated in the development of a number of human diseases including cancer, auto-immune and chronic inflammatory conditions [3,7,8]. Therefore, inhibitors of the NF-κB signaling pathway could offer potential therapeutic value for the treatment of such diseases [9,10].

The IκB kinase is a multi-component complex composed of two catalytic subunits, IKKα and IKKβ and a regulatory unit NF-κB essential modulator (NEMO) [11-13]. Although both catalytic units are able to phosphorylate IκB, IKKβ has been shown to play the dominant role in activating NF-κB signaling in response to inflammatory stimuli [14,15]. Phosphorylated IκB is subsequently tagged by the E1 ubiquitin enzyme and degraded by the proteasome to liberate active NF-κB. Free NF-κB then translocates into the nucleus, where it binds to its cognate DNA site and enhances the expression of a number of genes related to the immune response, cell proliferation and survival [16,17]. Consequently, IKKβ represents an attractive target in the NF-κB pathway for the development of anti-inflammatory or anti-cancer therapeutics.

Virtual screening (VS) has emerged as a powerful tool in drug discovery complementing the vast array of popular but relatively costly high-throughput screening technologies [18,19]. Using virtual screening, the number of compounds to be evaluated in vitro could be dramatically decreased, which could greatly reduce the time and resource costs of drug discovery efforts. Meanwhile, natural products (NPs) have long provided a valuable source of inspiration to medicinal chemists due to the diversity of their molecular scaffolds, favourable biocompatibility and evolutionarily validated bioactive substructures [20,21]. Combining these two ideas, our group has previously identified natural product or small molecule inhibitors antagonizing cancer or inflammation-related targets using virtual screening [22-28]. For example, we have successfully identified natural product or natural product-like compounds targeting the c-myc oncogene G-quadruplex, tumor necrosis factor-alpha (TNF-α) and NEDD8-activating enzyme (NAE) [29-34].

In recent years, many small molecule inhibitors of IKKβ have been identified using pharmacophore-based or high-throughput screening approaches [32-39]. However, the recent publication of the IKKβ X-ray crystal structure with its inhibitor [40] enables the use of powerful structure-based in silico methods for the discovery of novel IKKβ inhibitors. We thus set out to identify interesting molecular scaffolds for the development of future IKKβ inhibitors from a large natural product library using high-throughput structure-based virtual screening. The X-ray co-crystal structure of the IKKβ with the reference inhibitor ((4-{[4-4-chlorophenyl)pyrimidin-2-yl]amino}phenyl[4-(2-hydroxyethyl)piperazin-1-yl]methanone (PDB: 3RZF) was used for our molecular modeling investigations (Figure 1) [40]. To our knowledge, this work is the first example of an IKKβ inhibitor identified using high-throughput molecular docking of a natu-ral product database against the IKKβ X-ray co-crystal structure.

thumbnailFigure 1. Chemical structures of the small molecule IKKβ inhibitors. Chemical structures of IKKβ inhibitors (4-{[4-(4-chlorophenyl)phyrimidin2-yl]amino}phenyl[4-(2-hydroxyethyl)piperazin-1-yl]methanone (reference compound) (left) and NP-derived benzoic acid derivative (1) (right).

Results and Discussion

High-throughput virtual screening

The workflow of this virtual screening (VS) campaign is outlined in Scheme 1. The molecular model of IKKβ for VS was built using the recently reported X-ray co-crystal structure of IKKβ with its inhibitor. The binding site of IKKβ was defined to be within 3Å of the bound inhibitor, which is situated at the hinge loop connecting the N and C lobes of the IKKβ KD domain. Over 90,000 structures from a chemical library of natural products and natural product-like compounds were screened in silico against the binding pocket of IKKβ [31]. The flexible ligands were docked to a grid representation of the receptor and assigned a score reflecting the quality of the complex according to the Internal Coordinate Mechanics (ICM) method [ICM-Pro 3.6-1d molecular docking software (Molsoft)]. Compounds with ICM docking scores of under -30 kcal/mol were shortlisted. Based on visual inspection and availability from the commercial sources, 12 compounds containing distinctive chemical scaffolds were chosen (Additional file 1: Figure S1). These compounds were purchased and were subjected to a preliminary luciferase assay (Additional file 1: Figure S2). The results showed that 4 out of the 12 compounds were able to inhibit NF-κB transcription activity by 20% or more compared to the untreated control at a concentration of 20 μM. The benzoic acid derivative (1) (Figure 1) inhibited NF-κB activity by over 40% relative to the untreated control, while compounds 3, 9 and 10 exhibited weaker inhibitory activities of 20–30%. Compounds containing the benzoic acid moiety are known to display a variety of pharmacological effects and a number of benzoic acid derivatives possessing anti-inflammatory properties have been isolated from natural sources. For example, (E)-3-acetyl-6-(3,7-dimethylocta-2,6-dienyloxy)-2,4-dihydroxybenzoic acid isolated from M. semecarpifolia has been reported to suppress fmet-Leu-Phe (fMLP)-induced superoxide anion generation and elastase release by human neutrophils (Additional file 1: Table S1) [41]. In addition, the natural benzenoid antrocamphin A extracted from the fruiting body of A. camphorata was found to down-regulate iNOS and COX-2 expression at both transcriptional and translational levels via suppression of NF-κB nuclear translocation [42]. A synthetic benzoic acid-derived compound GS143 reported by Furuichi, Shimbara and co-workers blocked NF-κB translocation through inhibition of IκBα ubiquitination and subsequent IκBα degradation [43]. To our knowledge, no biological activity of 1 has been reported in the literature. The identification of this natural product-derived benzoic acid scaffold as an IKKβ inhibitor could contribute to an understanding of the molecular mechanisms of the anti-inflammatory properties of this class of compounds. Furthermore, we envisage that this natural product derivative could serve as a valuable scaffold for the development of future IKKβ inhibitors.

Additional file 1. Figure S1. Chemical structures of the 11 other high-scoring compounds selected for preliminary biological evaluation. Figure S2. Preliminary experimental screening of the 12 compounds on inhibition of cellular IKKβ mediated NF-κB activity. Table S1. Chemical name and structures of benzoic acid derivatives reported to target the NF-κB signaling pathway. Table S2. Lowest-energy binding pose of the 11 other compounds with the ATP binding site in the KD domain of IKKβ. Table S3. Binding poses and ICM docking energies of compound 1 to other four kinases. The reference compounds are displayed in cyan.

Format: DOCX Size: 6.9MB Download fileOpen Data

Scheme 1

Schematic diagram showing the workflow of this high-throughput molecular docking campaign.

Molecular modeling analysis

The ATP binding site of kinases generally consists of a narrow and hydrophobic region located between the N-lobe and C-lobe of the kinase domain (KD), with the two lobes linked together by a hinge region consisting of hydrogen bond donor and acceptor residues from the protein backbone [44]. The most important receptor residue in determining kinase inhibitor specificity is the “gatekeeper” residue, which controls the access of the inhibitor to the hydrophobic pocket. In the crystal structure of IKKβ, the gatekeeper residue is Met96, while Glu97, Tyr98 and Cys99 form the hinge region of the KD of IKKβ. The backbone groups of Glu97 and Cys99 are able to provide hydrogen bonding interactions with the inhibitor. In addition, the ATP binding site of IKKβ is partly covered by an activation loop comprised of serine, threonine and tyrosine residues in the unphosphorylated state. In particular, the N-terminal side of the activation loop contains the Asp166, Leu167 and Gly168 DLG triad which is involved in catalytic transfer of the γ-phosphate group in most kinase ATP binding sites (Figure 2a) [40].

thumbnailFigure 2. Molecular docking analysis of reference compound and 1 to the IKKβ protein complex. a) The KD domain of IKKβ is displayed in the ribbon form. The activation loop, gatekeeper residue (Met 96), hinge region (Glu97-Cys99) are visualized. Low-energy binding conformations of b) 1 and c) reference compound to IKKβ protein complex were generated by virtual ligand docking. Small molecules inhibitor 1 and reference compound is depicted as a ball-and-stick model showing carbon (yellow), hydrogen (grey), oxygen (red) and nitrogen (blue) atoms. H-bonds are indicated as dotted lines. The binding pocket of the IKKβ is represented as a translucent green surface.

Our molecular docking analysis revealed that the top-scoring binding mode of the natural product derivative 1 to the IKKβ complex is similar to that of the reference compound. The bound inhibitor in the co-crystal structure of IKKβ interacts with the ATP binding pocket in shape-driven manner [40]. While the structure of the reference compound contains the anilinopyrimidine motif that is found in other kinase inhibitors such as imatinib [45], no detectable hydrogen bonds between the hinge region of IKKβ and the anilinopyrimidine moiety of the reference compound were recorded. The aromatic rings of the reference compound span the hinge loop while its terminal chlorine atom points towards the gatekeeper residue Met96 (Figure 2b).

By comparison, the benzoic acid moiety of 1 is situated at the end of the hinge loop with predicted hydrogen bonding interactions between the carboxyl oxygen and amide oxygen atoms of 1 with the phenolic hydrogen atom of Tyr98 and the backbone amino group of Gly102, respectively (Figure 2c). The pendant side chain of 1 is predicted to be situated in a hydrophobic binding pocket also occupied by the reference compound. We envisage that 1 could act as a reversible inhibitor of IKKβ by blocking the nucleotide recognition domain that binds ATP [40]. The binding score for 1 with the IKKβ complex was calculated to be -35.28 kcal/mol, reflecting a strong interaction between the compound and the IKKβ binding site.

The other eleven compounds were also predicted to situate in the hinge region of the binding pockets in the docking analysis. Most of the compounds could form hydrogen bonds with the hinge residues including Glu97, Cys99 and Glu100. Furthermore, several of the compounds formed additional hydrogen bonds with the residues in the solvent accessible region (Arg31 and Lys106). The lowest energy binding pose of the other compounds are summarized in Additional file 1: Table S2.

We also investigated the selectivity of compound 1 for IKKβ over four other kinases (PKCα, PAK4, CaMK2α and JAK2) using molecular modeling. While compound 1 was predicted to bind at the ATP binding sites of the four other kinases, the ICM docking energies of the 1-kinase complexes were significantly less negative than that for IKKβ (Additional file 1: Table S3). Molecules exhibiting such weak binding energies would be expected to be inactive in vitro.

1 inhibits IκBα phosphorylation in vitro

Encouraged by the molecular docking results and the preliminary luciferase screening experiment, we investigated the effect of compound 1 on IKKβ phosphorylation activity. Inhibition of IKKβ phosphorylation activity would be expected to lead to a decrease in GST-IκBα substrate phosphorylation level. Encouragingly, a dose-dependent reduction in IKKβ activity was observed upon the incubation with 1, with an estimated IC50 value of ca. 50 μM (Figure 3).

thumbnailFigure 3. Inhibition of IKKβ phosphorylation activity. Microtiter plates with GST-IκBα were incubated with IKKβ together with 1 at the indicated concentrations. GST-IκBα phosphorylated level was detected using an anti-phospho IκBα (Ser32/Ser36) antibody and horseradish peroxidase conjugated secondary antibody. Approximate IC50 value of 1 = 50 μM. Error bars represent the standard deviations of the results from three independent experiments.

1 inhibits TNF-α induced NF-κB signaling in a HepG2 cell line

We sought to investigate the ability of compound 1 to inhibit NF-κB signaling in human cells using a luciferase assay. A stably-transfected HepG2 cell line carrying the luciferase reporter gene driven by a promoter containing multiple copies of the NF-κB response element was used in this study. The transcriptional activity of NF-κB was determined by measuring the luciferase activity of the cell lysates using a luminometer. We performed a dose response analysis of compound 1 and three other hit compounds in attenuating TNF-α-induced NF-κB signaling (Figure 4). Compound 1 inhibited TNF-α-induced luciferase activity in a dose-dependent manner with an estimated IC50 value of ca. 10 μM. While the three other compounds also inhibited TNF-α-induced luciferase activity, their inhibition potencies were around 10-fold lower compared to compound 1.

thumbnailFigure 4. Inhibition of cellular IKKβ mediated NF-κB activity. HepG2 cells stably transfected with the NF-κB–luciferase gene were stimulated with TNF-α pre-incubated with the indicated concentrations of 1 and other three hit compounds (compounds 3, 9 and 10). Cell lysates were analyzed for luciferase activity to determine the extent of NF-κB inhibition. Error bars represent the standard deviations of the results from three independent experiments.

Based on the results of the IKKβ assay and the molecular modeling analysis, we envisage that the inhibition of TNF-α-induced NF-κB signaling by 1 could be attributed, at least in part, to the inhibition of IKKβ activity in vitro, thus preventing the degradation of the NF-κB repressor IκBα. The slightly higher potency of 1 in the cell-based luciferase assay compared to the enzyme assay is possibly due to a multi-target effect of 1, suggesting that this compound could potentially influence other steps involved in NF-κB activation.

Conclusions

In conclusion, we have discovered a new small molecule IKKβ inhibitor from a large natural product library of 90,000 compounds using high-throughput structure-based molecular docking. The benzoic acid derivative 1 is able to inhibit IKKβ activity in both cell-free and system with micromolar potency. Furthermore, compound 1 could inhibit IKKβ-mediated NF-κB signaling pathway in human cancer cells. We envisage that compound 1 attenuates the in cellulo transcriptional activity of NF-κB, at least in part, by abrogating the activity of IKKβ. The discovery of this natural product-like derivative provides medicinal chemists with a structurally interesting scaffold, facilitating further chemical modifications in order to sample greater regions of the chemical space of potential IKKβ inhibitors. We are currently investigating the effects of 1 on the proteins involved in NF-κB signaling and conducting in silico lead optimization to generate more potent analogues of 1 for in vitro biological testing.

Methods

Materials and cell lines

The NP/NP-like compound collection, which includes compound 1 and the other tested compounds, was obtained from InterBioScreen (Moscow, RUS). The K-LISA™ IKKβ Inhibitor Screening Kit was obtained from Calbiochem (Darmstadt, Germany). Passive lysis buffer and luciferase assay reagent were obtained from Promega Corporation (Madison, WI, USA). HepG2 and HepG2-NF-κB-Luc cells were provided by Prof. Y.C. Cheng (Department of Pharmacology, Yale University School of Medicine, USA). Cells cultured in Minimum Essential Media containing 10% fetal bovine serum were incubated at 37°C/5% CO2 and passaged three times a week.

IKKβ enzymatic activity

IKKβ activity was determined using the ELISA-based (K-LISA™) IKKβ Inhibitor Screening Kit according to the manufacturer’s instructions. The GST-IκBα 50-amino acid peptide that includes the Ser32 and Ser36 IKKβ phosphorylation sites was used as a substrate and was incubated for 30 min at 30°C with human recombinant IKKβ in the presence of DMSO vehicle or different concentrations of 1 in a glutathione-coated 96-well plate. The phosphorylated GST-IκBα substrate was subsequently detected using anti-phospho-IκBα (Ser32/Ser36) antibody and a horseradish peroxidase-conjugated secondary antibody. The samples were finally incubated with TMB solution, and the color development was monitored at 450 nm on a plate reader (Bio-Rad).

NF-κB transactivation activity

Exponentially growing HepG2-NF-κB-Luc cells were seeded overnight at 1 × 104 cells/well in a 48-well plate. On the next day, the cells were pre-incubated with the indicated concentrations of 1 for 1 h before stimulation by 5 ng/mL of TNF-α for an additional 3 h. Passive lysis buffer (50 μL) was added to each well and the plate was incubated for 15 min with shaking. A 20 μL aliquot from each well was mixed with 70 μL luciferase assay reagent in a 96-well white plate. The transcriptional activity was determined by measuring the activity of firefly luciferase in a multi-well plate luminometer (Fusion α-FP, Perkin-Elmer).

Molecular modeling

A natural product or natural product-like chemical library containing over 90,000 compounds was screened in silico. Molecular docking was performed by using the ICM-Pro 3.6-1d program (Molsoft). According to the ICM method, the molecular system was described by using internal coordinates as variables. Energy calculations were based on the ECEPP/3 force field with a distance-dependent dielectric constant. The biased probability Monte Carlo (BPMC) minimization procedure was used for global energy optimization. The BPMC global-energy-optimization method consists of 1) a random conformation change of the free variables according to a predefined continuous probability distribution; 2) local-energy minimization of analytical differentiable terms; 3) calculation of the complete energy including nondifferentiable terms such as entropy and solvation energy; 4) acceptance or rejection of the total energy based on the Metropolis criterion and return to step (1). The binding between the small molecules and NAE-NEDD8 were evaluated with a full-atom ICM ligand binding score from a multireceptor screening benchmark as a compromise between approximated Gibbs free energy of binding and numerical errors. The score was calculated by:

<a onClick="popup('http://www.biomedcentral.com/2050-6511/14/3/mathml/M1','MathML',630,470);return false;" target="_blank" href="http://www.biomedcentral.com/2050-6511/14/3/mathml/M1">View MathML</a>

where Evw, Eel, Ehb, Ehp, and Esf are Van der Waals, electrostatic, hydrogen bonding, and nonpolar and polar atom solvation energy differences between bound and unbound states, respectively. Eint is the ligand internal strain, ΔSTor is its conformational entropy loss upon binding, and T = 300 K, and αi are ligand- and receptor independent constants. The initial model of IKKβ was built from the X-ray crystal structure of the Inhibitor of kappaB kinase beta (PDB: 3RZF) according to a previously reported procedure. Hydrogen and missing heavy atoms were added to the receptor structure followed by local minimization by using the conjugate gradient algorithm and analytical derivatives in the internal coordinates. In the docking analysis, the binding site was assigned across the entire structure of the protein complex. Each compound was assigned the MMFF force field atom types and charges and was then subjected to Cartesian minimization. The ICM docking was performed to find the most favorable orientation. The resulting trajectories of the complex between the small molecules and protein complex were energy minimized, and the interaction energies were computed. Each compound was docked three times and the minimum of the three scores was used. The 12 highest scoring compounds were utilized for biological testing without further selection. The crystal structures of PAK4 (4APP), PKCα (3IW4), CAMK2α (2VZ6) and JAK2 (3IOK) were also prepared and compound 1 was docked to these molecular models individually using the aforementioned procedures.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

C.-H. Leung and D.-L. Ma conceived the study, designed the experiments and performed the in silico high-throughput screening. Y.-W. Li and D. S.-H. Chan analyzed the experimental results, performed the experiments and wrote the manuscript. C.-H. Leung, D.-L. Ma and W.-F. Fong analyzed the experimental results and edited the manuscript. All authors have read and approved the final manuscript.

Acknowledgements

This work is supported by Hong Kong Baptist University (FRG2/11-12/009), Centre for Cancer and Inflammation Research, School of Chinese Medicine (CCIR-SCM, HKBU), the Health and Medical Research Fund (HMRF/11101212), the Research Grants Council (HKBU/201811 and HKBU/204612), the Science and Technology Development Fund, Macao SAR (001/2012/A) and the University of Macau MYRG091(Y1-L2)-ICMS12-LCH and MYRG121(Y1-L2)-ICMS12-LCH).

References

  1. Hayden MS, Ghosh S: Shared Principles in NF-κB Signaling.

    Cell 2008, 132:344-362. PubMed Abstract | Publisher Full Text OpenURL

  2. Vallabhapurapu S, Karin M: Regulation and Function of NF-κB Transcription Factors in the Immune System.

    Annu Rev Immunol 2009, 27:693-733. PubMed Abstract | Publisher Full Text OpenURL

  3. Karin M: Nuclear factor-κB in cancer development and progression.

    Nature 2006, 441:431-436. PubMed Abstract | Publisher Full Text OpenURL

  4. Baldwin AS: The NF-κB AND IκB Proteins: New Discoveries and Insights.

    Annu Rev Immunol 1996, 14:649-681. PubMed Abstract | Publisher Full Text OpenURL

  5. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al.: NF-κB as a Therapeutic Target in Multiple Myeloma.

    J Biol Chem 2002, 277:16639-16647. PubMed Abstract | Publisher Full Text OpenURL

  6. Schmid JA, Birbach A: IκB kinase β (IKKβ/IKK2/IKBKB)—A key molecule in signaling to the transcription factor NF-κB.

    Cytokine Growth Factor Rev 2008, 19:157-165. PubMed Abstract | Publisher Full Text OpenURL

  7. Lee CH, Jeon Y-T, Kim S-H, Song Y-S: NF-κB as a potential molecular target for cancer therapy.

    Biofactors 2007, 29:19-35. PubMed Abstract | Publisher Full Text OpenURL

  8. Karin M, Cao Y, Greten FR, Li Z-W: NF-κB in cancer: from innocent bystander to major culprit.

    Nat Rev Cancer 2002, 2:301-310. PubMed Abstract | Publisher Full Text OpenURL

  9. Kim HJ, Hawke N, Baldwin AS: NF-κB and IKK as therapeutic targets in cancer.

    Cell Death Differ 2006, 13:738-747. PubMed Abstract | Publisher Full Text OpenURL

  10. Senftleben U: Anti-inflammatory interventions of NF-κB signaling: Potential applications and risks.

    Biochem Pharmacol 2008, 75:1567-1579. PubMed Abstract | Publisher Full Text OpenURL

  11. Gilmore TD: Introduction to NF-κB: players, pathways, perspectives.

    Oncogene 2005, 25:6680-6684. OpenURL

  12. Perkins ND: Integrating cell-signaling pathways with NF-[kappa]B and IKK function.

    Nat Rev Mol Cell Biol 2007, 8:49-62. PubMed Abstract | Publisher Full Text OpenURL

  13. Karin M, Ben-Neriah Y: Phosphorylation Meets Ubiquitination: The Control of NF-κB Activity.

    Annu Rev Immunol 2000, 18:621-663. PubMed Abstract | Publisher Full Text OpenURL

  14. Karin M: How NF-κB is activated: the role of the IκB kinase (IKK) complex.

    Oncogene 1999, 18:6867-6874. PubMed Abstract | Publisher Full Text OpenURL

  15. Strnad J, Burke JR: IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges.

    Trends Pharmacol Sci 2007, 28:142-148. PubMed Abstract | Publisher Full Text OpenURL

  16. Karin M, Yamamoto Y, Wang QM: The IKK NF-κB system: a treasure trove for drug development.

    Nat Rev Drug Discov 2004, 3:17-26. PubMed Abstract | Publisher Full Text OpenURL

  17. Gilmore TD: The Rel/NF-B signal transduction pathway: introduction.

    Oncogene 1999, 18:6842-6844. PubMed Abstract | Publisher Full Text OpenURL

  18. Bajorath J: Integration of virtual and high-throughput screening.

    Nat Rev Drug Discov 2002, 1:882-894. PubMed Abstract | Publisher Full Text OpenURL

  19. Shoichet BK: Virtual screening of chemical libraries.

    Nature 2004, 432:862-865. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  20. Breinbauer R, Vetter IR, Waldmann H: From Protein Domains to Drug Candidates—Natural Products as Guiding Principles in the Design and Synthesis of Compound Libraries.

    Angew Chem Int Ed 2002, 41:2878-2890. Publisher Full Text OpenURL

  21. Ertl P, Roggo S, Schuffenhauer A: Natural Product-likeness Score and Its Application for Prioritization of Compound Libraries.

    J Chem Inf Model 2007, 48:68-74. PubMed Abstract | Publisher Full Text OpenURL

  22. Leung C-H: Chan DS-H, Kwan MH-T, Cheng Z, Wong C-Y, Zhu G-Y, Fong W-F, Ma D-L: Structure-Based Repurposing of FDA-Approved Drugs as TNF-α Inhibitors.

    ChemMedChem 2011, 6:765-768. PubMed Abstract | Publisher Full Text OpenURL

  23. Chan DS-H, Yang H, Kwan MH-T, Cheng Z, Lee P, Bai L-P, Jiang Z-H, Wong C-Y, Fong W-F, Leung C-H, Ma D-L: Structure-based optimization of FDA-approved drug methylene blue as a c-myc G-quadruplex DNA stabilizer.

    Biochimie 2011, 93:1055-1064. PubMed Abstract | Publisher Full Text OpenURL

  24. Yang H, Zhong H-J, Leung K-H, Chan DS-H, Ma VP-Y, Fu W-C, Nanjunda R, Wilson WD, Ma D-L, Leung C-H: Structure-based design of flavone derivatives as c-myc oncogene down-regulators.

    Eur J Pharm Sci 2013, 48:130-141. PubMed Abstract | Publisher Full Text OpenURL

  25. Ma D-L: Chan DS-H, Leung C-H: Molecular docking for virtual screening of natural product databases.

    Chem. Sci 2011, 2:1656-1665. Publisher Full Text OpenURL

  26. Ma D-L: Chan DS-H, Lee P, Kwan MH-T, Leung C-H: Molecular modeling of drug–DNA interactions: Virtual screening to structure-based design.

    Biochimie 2011, 93:1252-1266. PubMed Abstract | Publisher Full Text OpenURL

  27. Ma D-L: Ma VP-Y, Chan DS-H, Leung K-H, Zhong H-J, Leung C-H: In silico screening of quadruplex-binding ligands.

    Methods 2012, 57:106-114. PubMed Abstract | Publisher Full Text OpenURL

  28. Ma D-L, Chan DS-H, Leung C-H: Drug repositioning by structure-based virtual screening.

    Chem Soc Rev Publisher Full Text OpenURL

  29. Leung C-H, Chan DS-H, Yang H, Abagyan R, Lee SM-Y, Zhu G-Y, Fong W-F, Ma D-L: A natural product-like inhibitor of NEDD8-activating enzyme.

    Chem Commun 2011, 47:2511-2513. Publisher Full Text OpenURL

  30. Ma D-L, Lai T-S, Chan F-Y, Chung W-H, Abagyan R, Leung Y-C, Wong K-Y: Discovery of a Drug-Like G-Quadruplex Binding Ligand by High-Throughput Docking.

    ChemMedChem 2008, 3:881-884. PubMed Abstract | Publisher Full Text OpenURL

  31. Chan DS-H, Lee H-M, Yang F, Che C-M, Wong CCL, Abagyan R, Leung C-H, Ma D-L: Structure-Based Discovery of Natural-Product-like TNF-α Inhibitors.

    Angew Chem Int Ed 2010, 49:2860-2864. Publisher Full Text OpenURL

  32. Lee H-M: Chan DS-H, Yang F, Lam H-Y, Yan S-C, Che C-M, Ma D-L, Leung C-H: Identification of natural product Fonsecin B as a stabilizing ligand of c-myc G-quadruplex DNA by high-throughput virtual screening.

    Chem Commun 2010, 46:4680-4682. Publisher Full Text OpenURL

  33. Zhong H-J: Ma VP-Y, Cheng Z, Chan DS-H, He H-Z, Leung K-H, Ma D-L, Leung C-H: Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening.

    Biochimie 2012, 94:2457-2460. PubMed Abstract | Publisher Full Text OpenURL

  34. Ma D-L, Chan DS-H, Fu W-C, He H-Z, Yang H, Yan S-C, Leung C-H: Discovery of a Natural Product-Like c-myc G-Quadruplex DNA Groove-Binder by Molecular Docking.

    PLoS One 2012, 7:e43278. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  35. Miller DD, Bamborough P, Christopher JA, Baldwin IR, Champigny AC, Cutler GJ, Kerns JK, Longstaff T, Mellor GW, Morey JV, et al.: 3,5-Disubstituted-indole-7-carboxamides: The discovery of a novel series of potent, selective inhibitors of IKK-β.

    Bioorg Med Chem Lett 2011, 21:2255-2258. PubMed Abstract | Publisher Full Text OpenURL

  36. Crombie AL, Sum F-W, Powell DW, Hopper DW, Torres N, Berger DM, Zhang Y, Gavriil M, Sadler TM, Arndt K: Synthesis and biological evaluation of tricyclic anilinopyrimidines as IKKβ inhibitors.

    Bioorg Med Chem Lett 2010, 20:3821-3825. PubMed Abstract | Publisher Full Text OpenURL

  37. Kempson J, Spergel SH, Guo J, Quesnelle C, Gill P, Belanger D, Dyckman AJ, Li T, Watterson SH, Langevine CM, et al.: Novel Tricyclic Inhibitors of IκB Kinase.

    J Med Chem 2009, 52:1994-2005. PubMed Abstract | Publisher Full Text OpenURL

  38. Kempson J, Guo J, Das J, Moquin RV, Spergel SH, Watterson SH, Langevine CM, Dyckman AJ, Pattoli M, Burke JR, et al.: Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IκB kinase.

    Bioorg Med Chem Lett 2009, 19:2646-2649. PubMed Abstract | Publisher Full Text OpenURL

  39. Christopher JA, Bamborough P, Alder C, Campbell A, Cutler GJ, Down K, Hamadi AM, Jolly AM, Kerns JK, Lucas FS, et al.: Discovery of 6-Aryl-7-alkoxyisoquinoline Inhibitors of IκB Kinase-β (IKK-β).

    J Med Chem 2009, 52:3098-3102. PubMed Abstract | Publisher Full Text OpenURL

  40. Xu G, Lo Y-C, Li Q, Napolitano G, Wu X, Jiang X, Dreano M, Karin M, Wu H: Crystal structure of inhibitor of κB kinase β.

    Nature 2011, 472:325-330. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  41. Chen J-J, Cho J-Y, Hwang T-L, Chen I-S: Benzoic Acid Derivatives, Acetophenones, and Anti-inflammatory Constituents from Melicope semecarpifolia.

    J Nat Prod 2007, 71:71-75. PubMed Abstract | Publisher Full Text OpenURL

  42. Hsieh Y-H, Chu F-H, Wang Y-S, Chien S-C, Chang S-T, Shaw J-F, Chen C-Y, Hsiao W-W, Kuo Y-H, Wang S-Y: Antrocamphin A, an Anti-inflammatory Principal from the Fruiting Body of Taiwanofungus camphoratus, and Its Mechanisms.

    J Agric Food Chem 2010, 58:3153-3158. PubMed Abstract | Publisher Full Text OpenURL

  43. Nakajima H, Fujiwara H, Furuichi Y, Tanaka K, Shimbara N: A novel small-molecule inhibitor of NF-κB signaling.

    Biochem Biophys Res Commun 2008, 368:1007-1013. PubMed Abstract | Publisher Full Text OpenURL

  44. Ghose AK, Herbertz T, Pippin DA, Salvino JM, Mallamo JP: Knowledge Based Prediction of Ligand Binding Modes and Rational Inhibitor Design for Kinase Drug Discovery.

    J Med Chem 2008, 51:5149-5171. PubMed Abstract | Publisher Full Text OpenURL

  45. Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T: The Crystal Structure of a c-Src Complex in an Active Conformation Suggests Possible Steps in c-Src Activation.

    Structure 2005, 13:861-871. PubMed Abstract | Publisher Full Text OpenURL

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/2050-6511/14/3/prepub